RAYMOND FINK, M.D.
Endocrinology, Diabetes & Metabolism Physician in LA MESA, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
RAYMOND FINK, M.D. filed 228 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in LA MESA, California, prescribing 51% generic.
- 228
- Part D claims, 2023
- 51%
- generic prescribing
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
RAYMOND FINK, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2023 — across all CMS prescribers nationally
228 49th percentile higher than 49% of 1,370,886 prescribers
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Medicare Part D Prescriber Public Use File · 2023
RAYMOND FINK, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about RAYMOND FINK, M.D.?
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in California
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among California providers
Endocrinology, Diabetes & Metabolism Physician share within California
Endocrinology, Diabetes & Metabolism Physician is one of the more visible NUCC categories in California
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
Specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
RAYMOND FINK, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 8851 CENTER DR, LA MESA, CA, 91942, with a listed phone of (619) 463-1293. NPI 1164414652 was issued on 08/19/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what FINK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 228 prescription claims written by this provider, covering 114 Medicare beneficiaries and totaling roughly $118K in drug spend, split 49% brand-name and 51% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1164414652 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 08/19/2005 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm RAYMOND FINK, M.D.'s current license status, disciplinary history, and board certifications with the Medical Board of California in California before relying on this page for a clinical or care decision.
How we sourced this profile
License & disciplinary context — California MBC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to RAYMOND FINK, M.D.. To verify RAYMOND FINK, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
49% brand-name claims vs 51% generic, on 228 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 526
- Total Day Supply
- 15,557
- Brand vs Generic
- 49% brand / 51% generic
- Brand Drug Cost
- $115K
- Generic Drug Cost
- $3K
Patient Demographics
- Average Patient Age
- 75.1 years
- Avg HCC Risk Score
- 1.73
- Gender Split
- 47% female / 53% male
- Age Distribution
- <65: 12, 65-74: 42, 75-84: 43, 85+: 17
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What RAYMOND FINK, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Humalog Kwikpen U-…
Humalog Kwikpen U-100
19 claims
- Levothyroxine Sodium
Levothyroxine Sodium
18 claims
- Farxiga
Farxiga
14 claims
- Atorvastatin Calcium
Atorvastatin Calcium
13 claims
- Tresiba Flextouch …
Tresiba Flextouch U-200
12 claims
- Jardiance
Jardiance
11 claims
- Losartan Potassium
Losartan Potassium
11 claims
- Rosuvastatin Calcium
Rosuvastatin Calcium
11 claims
| Drug | Claims |
|---|---|
| Humalog Kwikpen U-100 Insulin Lispro | 19 |
| Levothyroxine Sodium | 18 |
| Farxiga Dapagliflozin Propanediol | 14 |
| Atorvastatin Calcium | 13 |
| Tresiba Flextouch U-200 Insulin Degludec | 12 |
| Jardiance Empagliflozin | 11 |
| Losartan Potassium | 11 |
| Rosuvastatin Calcium | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How RAYMOND FINK, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
RAYMOND FINK, M.D.'s 228 claims are below the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as FINK.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore California
Frequently Asked Questions
What is RAYMOND FINK, M.D.'s specialty? ▼
How much does RAYMOND FINK, M.D. prescribe under Medicare Part D? ▼
Where is RAYMOND FINK, M.D. located? ▼
What is RAYMOND FINK, M.D.'s NPI number? ▼
Does RAYMOND FINK, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does RAYMOND FINK, M.D. prescribe most often? ▼
Does RAYMOND FINK, M.D. accept Medicare? ▼
How can I verify RAYMOND FINK, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology